(Title of Presentation)(Subtitle of Presentation)

August 8, 2007

Hematologic Cancers Partners MeetingCenters for Disease Control and Prevention

May 16, 2008

2

The MMRF was founded in 1998 by a patient and her identical twin to deliver new treatment options to patients.

MARKET NEED

Incurable disease/no awareness

Limited research funding

MARKET FOCUS

Fund early promising research

Validate hypotheses

Reduce industry risk

Accelerate clinical trials

Deliver highest-quality education

MARKET EXPANSION

National Cancer Institute (NCI)

Pharmaceutical/Biotech industry

MMRF BackgroundMMRF Background

Educational FocusEducational Focus

With four new FDA-approved drugs in the past four years, 20 novel agents, and more than 200 clinical trials, patients and HCPs have numerous questions. MMRF educational efforts address these.

Clinical Approaches

Revlimid-based regimensVelcade-based regimensDoxil-VelcadeThal-combinationsStem cell transplantNovel agents

Myeloma BackgroundMyeloma Background

The incidence of myeloma is increasing. Underserved populations continue to be disproportionately affected.

High-risk populations

African-Americans (men)

Men

Veterans

Age 70+

Myeloma Inc idenc e

10,000

12,500

15,000

17,500

20,000

2004 2005 2006 2007 2008

Project GoalsProject Goals

Increase awareness of treatment options and clinical trials among healthcare providers and patients

Improve the reach and effectiveness of patient education strategies

Increase the awareness of MMRF resources among patients and providers

The MMRF’s CDC-supported outreach program has the following objectives:

AccomplishmentsAccomplishments

With initial CDC funding, MMRF efforts focused on identifying partners that reach the target population. The VA emerged as the top partner.

AccomplishmentsAccomplishments

The MMRF is the first and only organization to distribute educational materials through the VA system. With positive initial results, the partnership continues to grow.

Myeloma Initiative in VA (MIVA)

First-ever comprehensive program to educate patients and HCPs

Improve diagnosis and treatment

Create research collaborations across centers

MMRF tool-kits distributed to 170 centers

Program to serve as model for other diseases predominant in VHA

EvaluationEvaluation

The MMRF evaluates key metrics related to volume monthly. Online surveys with key partners are planned for Q2 2008.

Ongoing Measures of Success

•Total Tool-kits distributed• Total BRCs received

• CME post-test completions• Website visitors

• Patient Navigator profiles created; patients enrolled in trials

• Participants in MMRF educational programming

Planned Surveys

• Preferred format• Preferred frequency

• Information gaps

SustainabilitySustainability

To sustain the program, the MMRF must cultivate and expand its current partnerships and identify new partners to continue reach to target population.

Current Partners

VA Medical Centers

NCI-designated cancer centers/CCOPS

New Partners

• ACCC• US Oncology

• NMA• 100 Black Men

• NABVETS• NBLIC

• Hematologic Cancers Grantees?

VA Healthcare Systems

CBOCs

Regional Veterans Centers

MBCCOPs

Expansion Opportunities

Memorable MomentMemorable Moment

“Through MIVA, the MMRF provided patient and provider educational toolkits to the 170 VA medical centers. The kits provided both audiences with information tailored to their needs…This was the first time that the VA embarked on such a comprehensive disease-specific effort, and I believe this program could serve as a model for other diseases that are commonly seen in the veteran population.”

- Thakor G. Patel, MD, Former Program Chief, Renal Diseases,

Diabetes and Oncology at the Veterans Health Administration